Gastens Viktoria, Tancredi Stefano, Kiszio Blanche, Del Giovane Cinzia, Tsuyuki Ross T, Paradis Gilles, Chiolero Arnaud, Santschi Valérie
Population Health Laboratory (#PopHealthLab), University of Fribourg, Fribourg, Switzerland.
La Source, School of Nursing Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Lausanne, Switzerland.
Front Cardiovasc Med. 2025 Mar 14;12:1477729. doi: 10.3389/fcvm.2025.1477729. eCollection 2025.
Community-based models of care with the involvement of pharmacists and other nonphysician healthcare professionals can help improve blood pressure (BP) control. We aimed to synthesize the evidence of effectiveness of pharmacist interventions on BP among patients with hypertension.
We performed systematic searches to identify randomized controlled trials (RCTs) assessing the effect of pharmacist interventions on BP among outpatients (latest search, March 2024). The effect on systolic and diastolic BP change or BP control were pooled using random effects model. Subgroup analysis for the types of pharmacist interventions and healthcare settings were performed. The risk of bias was assessed using the Cochrane Risk of Bias Tool 2. The protocol was registered in PROSPERO (CRD42021279751) and published in an open-access peer-reviewed journal.
Out of 2,330 study records identified in 7 electronic databases, a total of 95 RCTs, with 31,168 participants (control 16,157, intervention 15,011), were included. The intervention was led by the pharmacist in 75% of the studies and in collaboration with other healthcare providers in 25%. Pharmacist interventions included patient education in 88%, feedback to healthcare providers in 49%, and patient reminders in 24% of the studies. Systolic and diastolic BP were reduced after pharmacist intervention by -5.3 mmHg (95% CI: -6.3 to -4.4; = 86%) and -2.3 mmHg (95% CI: -2.9 to -1.8; = 75%), respectively. The reduction of systolic BP tended to be larger if the intervention was collaborative, conducted in outpatient clinics, based on healthcare provider education, or through healthcare provider feedback. Analyses restricted to relatively large or high-quality studies yielded similar estimates, with lower between-studies heterogeneity.
Pharmacist care for patients with hypertension consistently improves BP across various settings and interventions. Pharmacist care is one key element of the solution to the global burden of hypertension and cardiovascular diseases.
CRD42021279751.
由药剂师和其他非医师医疗保健专业人员参与的社区护理模式有助于改善血压(BP)控制。我们旨在综合有关药剂师干预对高血压患者血压影响的有效性证据。
我们进行了系统检索,以识别评估药剂师干预对门诊患者血压影响的随机对照试验(RCT)(最新检索时间为2024年3月)。使用随机效应模型汇总对收缩压和舒张压变化或血压控制的影响。对药剂师干预类型和医疗保健环境进行亚组分析。使用Cochrane偏倚风险工具2评估偏倚风险。该方案已在PROSPERO(CRD42021279751)注册并发表在开放获取的同行评审期刊上。
在7个电子数据库中识别出的2330条研究记录中,共纳入95项RCT,涉及31168名参与者(对照组16157名,干预组15011名)。75%的研究中干预由药剂师主导,25%的研究中与其他医疗保健提供者合作。药剂师干预包括88%的患者教育、49%的向医疗保健提供者反馈以及24%的患者提醒。药剂师干预后,收缩压和舒张压分别降低了-5.3 mmHg(95%CI:-6.3至-4.4; = 86%)和-2.3 mmHg(95%CI:-2.9至-1.8; = 75%)。如果干预是合作性的、在门诊诊所进行、基于医疗保健提供者教育或通过医疗保健提供者反馈,收缩压的降低往往更大。限于相对大型或高质量研究的分析得出了类似的估计值,研究间异质性较低。
药剂师对高血压患者的护理在各种环境和干预措施中均能持续改善血压。药剂师护理是解决全球高血压和心血管疾病负担问题的关键要素之一。
PROSPERO注册号:CRD42021279751。